PT - JOURNAL ARTICLE AU - Ates, H. Ceren AU - Alshanawani, Abdallah AU - Hagel, Stefan AU - Cotta, Menino O AU - Roberts, Jason A AU - Dincer, Can AU - Ates, Cihan TI - Unraveling the Impact of Therapeutic Drug Monitoring via Machine Learning AID - 10.1101/2023.10.23.23297424 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.23.23297424 4099 - http://medrxiv.org/content/early/2023/10/25/2023.10.23.23297424.short 4100 - http://medrxiv.org/content/early/2023/10/25/2023.10.23.23297424.full AB - Clinical studies investigating the benefits of beta-lactam therapeutic drug monitoring (TDM) among critically ill patients have been hindered by small patient group, variability between studies, patient heterogeneity and inadequate use of TDM. Accordingly, definitive conclusions regarding the efficacy of TDM have remained elusive. To address these challenges, we propose an innovative approach that leverages data-driven methods to unveil the concealed connections between therapy effectiveness and patient data. Our findings reveal that machine learning algorithms can identify informative features that distinguish between healthy and sick states. These hold promise as potential markers for disease classification and severity stratification, as well as offering a continuous and data-driven “multidimensional” SOFA score. The implementation of TDM-guided therapy was associated with improved recovery rates particularly during the critical 72 hours after sepsis onset. Providing the first-ever quantification of the impact of TDM, our approach has the potential to revolutionize the way TDM applied in critical care.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT: 2016-000136-17Funding StatementH.C.A and C.D. would like to acknowledge the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) for funding this work (grant numbers 404478562 and 446617142). The TARGET study was funded by the Federal Ministry of Education and Research (BMBF), 01EO1502.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical data used in this study was already published under: Hagel, S., Bach, F., Brenner, T. et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med 48, 311-321 (2022). https://doi.org/10.1007/s00134-021-06609-6.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.